Francesca Trojsi is Associate Professor of Neurology at the University of Campania “Luigi Vanvitelli” in Naples (Italy) and Referent of the ALS Centre of University Hospital “Luigi Vanvitelli” in Naples (Italy). She had a Research Fellow at the “MRI Research Center SUN-FISM” (Second University of Naples – Naples, Italy), from 2009 to 2010, and was PhD in “Experimental Physiopathology and Neurosciences” (Second University of Naples, Naples, Italy) performing the PhD research project “Structural and functional markers in Amyotrophic Lateral Sclerosis (ALS) as detected by advanced neuroimaging techniques”. She was Assistant Professor of Neurology at the University of Campania “Luigi Vanvitelli” in Naples (Italy) from 2014 to 2021. She is Associate Editor of the section “Neurodegeneration” of “Frontiers in Neuroscience” (2014-today), and of “Orphanet Journal of Rare Diseases” (2021-today). She is Academic Editor of “Brain Sciences” (MDPI) (2020-today). Her main areas of research are neuroimaging/clinical trials applied to ALS and dementia. She is member of the EUROPEAN REFERENCE NETWORK (ERN) Euro Neuromuscular Disorders (NMD) within the Healthcare Provider University Hospital “Luigi Vanvitelli” (2016-today) and member of the Italian ALS Genetic (ITALSGEN) Consortium (2012-today) and of the Neuroimaging Society in Amyotrophic Lateral Sclerosis (NiSALS) (2014-today).
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.